Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity

Stroke, Ischemic Clinical Trial

Official title:

Dose-finding Study of Selective Serotonin Reuptake Inhibitors to Enhance Neuroplasticity

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT04221256
• Other study ID #: HMRL-002
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: March 11, 2020
• Est. completion date: February 9, 2021

Study information

• Verified date: July 2021
• Source: Burke Medical Research Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The brain is able to change throughout life in response to learning, or injury, or to adapt to changes in the environment, which is known as neuroplasticity. Stroke survivors suffer disabling chronic motor impairments that have proven challenging to improve. Increasing neuroplasticity using selective serotonin reuptake inhibitors (SSRIs) is a promising approach to promote motor recovery in patients with stroke.

Description:

The brain is able to change throughout life in response to learning, or injury, or to adapt to changes in the environment, which is known as neuroplasticity. Stroke survivors suffer disabling chronic motor impairments that have proven challenging to improve. Increasing neuroplasticity using selective serotonin reuptake inhibitors (SSRIs) is a promising approach to promote motor recovery in patients with stroke. Selective serotonin reuptake inhibitors (SSRIs) are currently widely used for treatment of depression, but they also have been shown to be able to enhance neuroplasticity. A single dose of SSRI has been shown to improve hand function in patients with chronic stroke. SSRIs also enhance neuroplasticity in healthy individuals, as shown using paired associative stimulation (PAS), a non-invasive method which causes the brain's excitability to change. However, the best dose of SSRI to increase neuroplasticity is not yet established.

The purpose of this study is to (1) find the effective dose of the SSRI escitalopram to modulate PAS-induced plasticity in patients with stroke and healthy individuals and (2) determine the variability of escitalopram's effect on PAS-induced plasticity between individuals. We measure neuroplasticity with PAS, which causes the brain's excitability to change. During PAS, you would receive electrical stimulation over your wrist and magnetic stimulation to their scalp (called transcranial magnetic stimulation, or TMS) to increase the excitability of the motor area of the brain. You will be asked to participate in a screening visit and 8 study visits separated by at least 1 week. At each study visit, you will be given a single dose of escitalopram (5, 10 or 20) or placebo, and we will measure your brain's change in excitability after PAS.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: February 9, 2021
• Est. primary completion date: February 9, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Neurological Healthy Participants Inclusion criteria

1. Men and women aged 18 years and older.

2. Ability to give informed consent.

Exclusion criteria

1. Contraindications to TMS: epilepsy or other seizure history, ferromagnetic metallic implants in the head, or pacemaker

2. Current or history of neurological disorders or brain lesions such as stroke, multiple sclerosis, tumor, traumatic brain injury, spinal cord injury

3. Diagnosis of major depressive disorder or other psychiatric disorder

4. Currently taking escitalopram or another selective serotonin reuptake inhibitor

5. Currently taking or have taken in the past month other medications or supplements that have known interactions with escitalopram or can precipitate serotonin syndrome when taken in combination with escitalopram: monoamine oxidase inhibitors, methylene blue, linezolid, serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants (TCAs), fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's wort

6. Known hypersensitivity to escitalopram or any of its inactive ingredients.

7. History of cerebral hemorrhage, gastrointestinal bleeding, or genitourinary bleeding.

8. History of prolonged QTc

9. Pregnant or breastfeeding

10. Social and/or personal circumstances that interfere with the ability to return for all study visits.

Stroke Patients Inclusion criteria

1. Men and women aged 18 years and older.

2. Ability to give informed consent.

3. History of ischemic stroke

Exclusion criteria

1. Contraindications to TMS: epilepsy or other seizure history, ferromagnetic metallic implants in the head, or pacemaker

2. Current or history of neurological disorders or brain lesions such as multiple sclerosis, tumor, traumatic brain injury, spinal cord injury

3. Diagnosis of major depressive disorder or other psychiatric disorder

4. Currently taking escitalopram or another selective serotonin reuptake inhibitor

5. Currently taking or have taken in the past month other medications or supplements that have known interactions with escitalopram or can precipitate serotonin syndrome when taken in combination with escitalopram: monoamine oxidase inhibitors, methylene blue, linezolid, serotonin norepinephrine reuptake inhibitors (SNRI), triptans, tricyclic antidepressants (TCAs), fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's wort

6. Known hypersensitivity to escitalopram or any of its inactive ingredients.

7. History of cerebral hemorrhage, gastrointestinal bleeding, or genitourinary bleeding.

8. History of prolonged QTc

9. Pregnant or breastfeeding

10. Social and/or personal circumstances that interfere with the ability to return for all study visits.

Related Conditions & MeSH terms

• Stroke, Ischemic

Intervention

Drug:
• Administration of SSRI escitalopram
Participants will be administered 5, 10 or 20mg of SRRI escitalopram prior to paired associative stimulation

Behavioral:
• Paired Associative stimulation
Participants will receive paired associative stimulation (transcranial magnetic stimulation and peripheral nerve stimulation) with an inter-stimulus interval length known to modulate corticospinal excitability.

Drug:
• Administration of Placebo
Participants will be administered a placebo prior to paired associative stimulation

Locations

Country	Name	City	State
United States	Burke Neurological Institute	White Plains	New York

Sponsors (1)

Lead Sponsor	Collaborator
Burke Medical Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in motor evoked potential amplitude	Assessment of corticospinal excitability	Baseline, Up to 30 minutes Post PAS